The preliminary results of the clinical trials for the treatment of patients with COVID-19 that are conducted in Moldova show the patients have a negative test on the second and third days. This means the treatment has a positive effect and the infected patients had a good recovery period, IPN reports.

According to the Medicines and Medical Devices Agency, the two clinical trials carried out in Moldova were started by U.S. pharmaceutical companies. These are performed at the National Clinical Hospital “Timofei Moșneaga” under the management of university professor Victor Cojocaru, who heads the Intensive Care Anesthesia Clinic, in concert with the German clinical research company ARENSIA Exploratory Medicine.

Since June, the Medicines and Medical Devices Agency has authorized six clinical trials intended for the treatment and prevention of COVID-19. These have been carried out under the surveillance of the National Committee for Ethics in Clinical Trial Expertise of the Ministry of Health, Labor and Social Protection and with the assistance of the State University of Medicine and Pharmacy “Nicolae Testemiţanu”.